AMSBIO: Lentivirus for miRNA Expression and Inhibition
AMSBIO has introduced a range of ready-to-use human and mouse lentivirus products for miRNA and anti-miRNA expression (miRNA inhibition). Lentiviral expression vectors are the most effective vehicles for delivering genetic material to almost any mammalian cell — including non-dividing cells and whole model organisms.
miRNAs are endogenous non-coding RNAs that are highly conserved in mammals and that regulate gene expression post-transcriptionally through innate RNA interference mechanisms. As key players in the fine-tuning of biological networks, miRNAs offer significant diagnostic and prognostic potential as biomarkers not only of fundamental cellular physiology but also of disease etiology and progression.
To study long-term miRNA-induced phenotypes, AMSBIO has developed a range of ready-to-use products for stable expression of the mature miRNA. There are more than 2000 mature miRNA discovered in human and more than 1200 miRNA in mouse so far. miRNA mainly silence or repress gene expression via binding to the complementary sequences of gene coding mRNA. Each miRNA can target multiple genes. It is believed than greater than 60% of mammalian gene expression is regulated by miRNAs, and miRNAs are involved in most biological processes, including a variety of diseases or disorders development.
AMSBIO's range of ready-to-use, anti-miRNA lentivirus (miRNA inhibitors) are produced from the optimally designed anti miRNA lentivectors. The annealed DNA oligonucleotides hairpin duplex encoding the antisense of a specific miRNA sequence are cloned under a constitutive human U6 promoter or under an optional inducible human H1 promoter. AMSBIO’s anti-miRNA lentivector was carefully designed for highest anti-miRNA expression level with precise promoter transcription position, and to favor the antisense strand for RISC complex processing.
Anti-miRNA or miRNA inhibitors are short RNA molecules complementary to the mature miRNA sequence. Anti miRNA specifically binds to endogenous miRNA and it inhibits or down-regulates miRNA activity. Therefore, anti-miRNA is a great tool for the loss of function research of any specific miRNAs. miRNA inhibitors also show potential as therapeutic agents for some biological malfunctions.
Related News
-
News CPHI Podcast Series: The power of proteins in antibody drug development
In the latest episode of the CPHI Podcast Series, Lucy Chard is joined by Thomas Cornell from Abzena to discuss protein engineering for drug design and development. -
News Amgen sues Samsung biologics unit over biosimilar for bone disease
Samsung Bioepis, the biologics unit of Samsung, has been issued a lawsuit brought forth by Amgen over proposed biosimilars of Amgen’s bone drugs Prolia and Xgeva. -
News CPHI Podcast Series: Why we need to consider women in clinical trials
The latest episode of the CPHI Podcast Series with Lucy Chard covers women's health, specifically women's representation in clinical trials, the associated bias, and the impacts on health for this population. -
News US FDA does not approve MDMA therapy for PTSD, requests more data
The MDMA-based therapeutic developed by Lykos Therapeutics, a California-based Public Benefit Corporation (PBC), has been reviewed and unapproved by the US FDA. The regulator has requested additional phase III trial data for further safety and efficacy... -
News Novartis and Viatris latest facing lawsuit over HeLa cell misuse
Global pharmaceutical companies Novartis and Viatris are the latest hit with a lawsuit claim pertaining to alleged misuse of the ‘HeLa’ cell line from the estate of woman whose cancerous tissue cells were taken without consent. -
News Sanofi invests billions into Frankfurt insulin production site
French pharmaceutical company Sanofi have announced an investment of EUR1.3 billion at their existing BioCampus site in Frankfurt am Main for the expansion of insulin production. -
News Novel oral Type 1 diabetes drug gains US FDA IND designation
A University of Alabama at Birmingham startup has gained FDA clearance for Investigational New Drug clinical trials for an oral Type 1 diabetes drug, a milestone for diabetes treatment. -
News A Day in the Life of a Vice President in R&D & Engineering
In the Day in the Life of Series, we've already had the chance to get to know a range of people in various roles in the pharma industry. In the latest interview we get a glimpse into the R&D side of things from Jennifer Sorrells, Vice Presiden...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance